Literature DB >> 25999245

Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Ersilia M DeFilippis1, Sonal Kumar2.   

Abstract

Nearly one-third of patients with inflammatory bowel disease (IBD) have abnormal liver tests, which can be indicative of underlying hepatic disease. Primary sclerosing cholangitis has a clear association with ulcerative colitis, but other autoimmune disorders such as autoimmune hepatitis (AIH) have also been associated with IBD. AIH may also occur in the setting of an overlap syndrome or in the setting of medications, particularly tumor necrosis factor alpha inhibitors. Importantly, some studies have shown that IBD patients with AIH fail treatment more frequently than IBD patients without AIH. This review will focus on the clinical characteristics, diagnosis, and management of autoimmune hepatitis in inflammatory bowel disease patients.

Entities:  

Keywords:  Abnormal liver function tests; Autoimmune hepatitis; Overlap syndromes; Primary biliary cirrhosis; Primary sclerosing cholangitis

Mesh:

Year:  2015        PMID: 25999245     DOI: 10.1007/s10620-015-3699-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  75 in total

1.  Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease.

Authors:  K Fellermann; M Steffen; J Stein; A Raedler; J Hämling; D Ludwig; K Loeschke; E F Stange
Journal:  Aliment Pharmacol Ther       Date:  2000-02       Impact factor: 8.171

2.  Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate.

Authors:  K Subramaniam; S Chitturi; M Brown; P Pavli
Journal:  Inflamm Bowel Dis       Date:  2011-08-30       Impact factor: 5.325

3.  Infliximab as rescue therapy in paediatric autoimmune hepatitis.

Authors:  Jeremy Rajanayagam; Peter J Lewindon
Journal:  J Hepatol       Date:  2013-06-17       Impact factor: 25.083

4.  Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.

Authors:  Marilia Cravo; Rosa Silva; Miguel Serrano
Journal:  BioDrugs       Date:  2010-12-14       Impact factor: 5.807

5.  Pediatric ulcerative colitis associated with autoimmune diseases: a distinct form of inflammatory bowel disease?

Authors:  Felipe Ordonez; Florence Lacaille; Danielle Canioni; Cecile Talbotec; Jean-Christophe Fournet; Nadine Cerf-Bensussan; Olivier Goulet; Jacques Schmitz; Frank M Ruemmele
Journal:  Inflamm Bowel Dis       Date:  2012-01-11       Impact factor: 5.325

Review 6.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.

Authors:  Rebecca Saich; Roger Chapman
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

7.  An atypical presentation for primary sclerosing cholangitis.

Authors:  V A Luketic; D A Gomez; A J Sanyal; M L Shiffman
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

8.  Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history.

Authors:  Mark Deneau; M Kyle Jensen; John Holmen; Marc S Williams; Linda S Book; Stephen L Guthery
Journal:  Hepatology       Date:  2013-08-13       Impact factor: 17.425

Review 9.  Diagnosis and management of the overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Can J Gastroenterol       Date:  2013-07       Impact factor: 3.522

10.  Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis.

Authors:  Christina Weiler-Normann; Christoph Schramm; Alexander Quaas; Christiane Wiegard; Claudia Glaubke; Nadine Pannicke; Sina Möller; Ansgar W Lohse
Journal:  J Hepatol       Date:  2012-11-21       Impact factor: 25.083

View more
  4 in total

Review 1.  Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver.

Authors:  Loris Riccardo Lopetuso; Giammarco Mocci; Manuela Marzo; Francesca D'Aversa; Gian Lodovico Rapaccini; Luisa Guidi; Alessandro Armuzzi; Antonio Gasbarrini; Alfredo Papa
Journal:  Int J Mol Sci       Date:  2018-07-27       Impact factor: 5.923

2.  KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis.

Authors:  Takeji Umemura; Satoru Joshita; Hiromi Saito; Kaname Yoshizawa; Gary L Norman; Eiji Tanaka; Masao Ota
Journal:  JHEP Rep       Date:  2019-10-25

Review 3.  Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations.

Authors:  Cristina Bezzio; Cristina Della Corte; Marta Vernero; Imma Di Luna; Gianpiero Manes; Simone Saibeni
Journal:  Therap Adv Gastroenterol       Date:  2022-07-28       Impact factor: 4.802

Review 4.  Liver manifestations and complications in inflammatory bowel disease: A review.

Authors:  Rui Gaspar; Catarina Castelo Branco; Guilherme Macedo
Journal:  World J Hepatol       Date:  2021-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.